Newsletter | January 28, 2021

01.28.21 -- How To Ratchet Up Biosimilar Competition In 2021

Featured Editorial
Industry Insights
Is Your Biologics At Risk For Protein Aggregation? Part 2

The manufacture of sterile injectables is fraught with risk, especially when it comes to protein aggregation in biologics drugs. We offer steps you can take to help prevent aggregation.

Why, Why, Why … ELISA? A Look At The Benchmark HCP Assay

Biologics developers and manufacturers demand an accurate and reliable assay for host cell protein (HCP) quantitation. Let’s take a close look at why analytical scientists turn to the ELISA and how it fits into process development.

Can mRNA Disrupt The Biopharma Industry?

mRNA has the potential to revolutionize the field of vaccine development. However, it is critical we understand any factors that could impact its successful entry into today’s market.

News Headlines